A 3D advanced test for prediction of drug response in secondary liver cancer

Project Information

SpheroPredict

Grant agreement ID: 734941

DOI

10.3030/734941

Project closed

EC signature date 16 December 2016

Start date 1 January 2017

End date 30 April 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SPHEROTEC GMBH
Germany

Periodic Reporting for period 1 - SpheroPredict (A 3D advanced test for prediction of drug response in secondary liver cancer)

Reporting period: 2017-01-01 to 2017-04-30

Summary of the context and overall objectives of the project

The treatment in secondary cancer is mainly based on the “trial and error approach”. This contributes to failure of patients’ response to chemotherapy and increase of their suffering.
SpheroPredict addresses this problem improving survival and quality of life in cancer patients. It is based on the spheroid model, which is 3D cell cultures from patients tumor samples that perfectly reproduce its response to chemotherapy drugs.
SPHEROPREDICT is an important issue for society regarding two pillars:
- Economical: The European economic impact imposed by cancer is estimated to be € 51 billion spent in healthcare and € 42.6 billion in productivity loss due to early death.
- Social: Secondary cancer is one of the leading causes of death worldwide and cancer is expected to lead to death over 11.5 million people by 2030 globally.
Objectives of the present feasibility study:
- Design a protocol of a large interventional study.
- Define a commercial strategy to reach our sales objectives.
- Built up the Work Plan. Define the sales plan and projections for the 5 years following the execution of Phase 2 project.
- Calculate the funding requirements for the execution of this project.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We optimized the protocol of a large interventional clinical study to confirm SpheroPredict’s effectiveness and cost-benefit analysis. We prepared for the necessary requirements for commercialization and we further defined our Business Plan. Finally, we planned the necessary Work Plan that will allow us to achieve a TRL9 and prepare for a large-scale commercialization.
From our market study we are a expecting a big demand for SpheroPredict and we found that the potential available market is very broad. We have set our sales plan and projections for the 5 years following the execution of Phase 2 project. We calculated the funding requirements that SpheroPredict project needs to reach the objectives and get to TRL 9. We also assessed the infrastructure investment we need to scale up the production capacity.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

SpheroPredict is a strong product, which can boost the market in the field of individualized therapeutic treatment of solid cancers. It will provide oncologists with an accurate to decide on the most effective chemotherapy their patients. It will improve the patient’s quality of life and provide significant cost savings to both the patient and the healthcare systems, decreasing economic losses due to ineffective therapy and to treatment-related side effects costs.

spherotec.png